Pulse Biosciences (PLSE) investors back all directors and Deloitte as 2026 auditor

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Pulse Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders, held virtually via live audio webcast on June 11, 2026. Stockholders voted on director elections and auditor ratification.

All seven director nominees, including Robert W. Duggan, Paul A. LaViolette, Maria Sainz, Manmeet S. Soni, Darrin R. Uecker, Richard A. van den Broek, and Mahkam Zanganeh, D.D.S., were elected to serve until the 2027 Annual Meeting and until their successors are duly elected and qualified. Support levels were high, with each nominee receiving more than 33.5 million votes “For” and relatively few votes “Against” or “Abstained,” alongside 10,974,550 broker non-votes.

Stockholders also ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 45,976,355 votes “For,” 8,265 “Against,” and 17,074 “Abstained.” This confirms both the company’s board composition for the coming year and its choice of external auditor.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for Deloitte & Touche LLP: 45,976,355 votes Votes against Deloitte & Touche LLP: 8,265 votes Abstentions on auditor ratification: 17,074 votes +4 more

7 metrics

Votes for Deloitte & Touche LLP 45,976,355 votes Ratification as independent registered public accounting firm for 2026

Votes against Deloitte & Touche LLP 8,265 votes Ratification of independent auditor for fiscal year ending December 31, 2026

Abstentions on auditor ratification 17,074 votes Deloitte & Touche LLP audit ratification proposal

Votes for Robert W. Duggan 33,443,582 votes Election as director until 2027 Annual Meeting

Votes against Robert W. Duggan 1,583,174 votes Director election at 2026 Annual Meeting

Broker non-votes on director elections 10,974,550 votes Each director nominee at 2026 Annual Meeting

Votes for Maria Sainz 35,007,101 votes Election as director until 2027 Annual Meeting

Key Terms

broker non-votes, independent registered public accounting firm, Annual Meeting of Stockholders, emerging growth company

4 terms

broker non-votes financial

"Broker Non-votes 10,974,550"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm regulatory

"ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Annual Meeting of Stockholders financial

"held its 2026 Annual Meeting of Stockholders"

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/12/2026 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 11, 2026

Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-37744	46-5696597
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3957 Point Eden Way
Hayward, California 94545
(Address of Principal Executive Offices) (Zip Code)
510-906-4600
(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share	PLSE	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07

SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

On June 11, 2026, Pulse Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting was a virtual meeting held via live audio webcast. The stockholders of the Company voted on the following items at the Annual Meeting:

to elect seven directors to hold office until the Company’s 2027 annual meeting and until their successors are duly elected and qualified, subject to earlier resignation or removal;

to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026;

The voting results for each of these proposals are detailed below:

Election of Directors

Nominee	For	Against	Abstained	Broker Non-votes
Robert W. Duggan	33,443,582	1,583,174	388	10,974,550
Paul A. LaViolette	34,264,295	759,401	3,448	10,974,550
Maria Sainz	35,007,101	18,349	1,694	10,974,550
Manmeet S. Soni	33,560,875	1,464,574	1,695	10,974,550
Darrin R. Uecker	34,246,413	779,036	1,695	10,974,550
Richard A. van den Broek	34,278,978	746,471	1,695	10,974,550
Mahkam Zanganeh, D.D.S.	34,241,938	783,511	1,695	10,974,550

Each director nominee was duly elected to serve until the 2027 Annual Meeting and until his or her successor is duly elected and qualified.

Ratification of Appointment of Independent Registered Public Accounting Firm

For		Against		Abstained		Broker Non-votes
45,976,355		8,265		17,074		N/A

The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PULSE BIOSCIENCES, INC.


Date: June 11, 2026	By:	/s/ Jon Skinner
		Jon Skinner
		Chief Financial Officer (Principal Financial Officer)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pulse Biosciences (PLSE) stockholders approve at the 2026 Annual Meeting?

Pulse Biosciences stockholders elected all seven director nominees and ratified Deloitte & Touche LLP as independent auditor for 2026. The meeting was held virtually, and voting results showed strong support for the board slate and the company’s choice of external accounting firm.

Were all Pulse Biosciences (PLSE) director nominees elected in 2026?

Yes, all seven Pulse Biosciences director nominees were elected to serve until the 2027 Annual Meeting. Each nominee, including Robert W. Duggan and Maria Sainz, received over 33.5 million votes in favor, with relatively low opposition and a significant number of broker non-votes reported.

How many votes supported Deloitte & Touche LLP as Pulse Biosciences’ 2026 auditor?

Stockholders cast 45,976,355 votes in favor of Deloitte & Touche LLP as Pulse Biosciences’ independent registered public accounting firm for 2026, with 8,265 votes against and 17,074 abstentions. This indicates broad shareholder backing for the company’s selected auditor for the upcoming fiscal year.

How was Pulse Biosciences’ 2026 Annual Meeting of Stockholders conducted?

Pulse Biosciences held its 2026 Annual Meeting of Stockholders as a virtual meeting via live audio webcast on June 11, 2026. Stockholders participated remotely to vote on the election of directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm.

What were the broker non-votes at the Pulse Biosciences (PLSE) 2026 meeting?

For the director election proposals, Pulse Biosciences reported 10,974,550 broker non-votes for each nominee. Broker non-votes occur when brokers hold shares in street name but are not instructed on non-routine matters, so those shares are not counted as votes for or against directors.

How many votes did Robert W. Duggan receive in the 2026 Pulse Biosciences director election?

Robert W. Duggan received 33,443,582 votes “For,” 1,583,174 votes “Against,” and 388 abstentions, with 10,974,550 broker non-votes. This result confirms his re-election to Pulse Biosciences’ board to serve until the 2027 Annual Meeting and until a successor is duly elected and qualified.

Filing Exhibits & Attachments

4 documents